Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer

NCT02901899 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02901899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02901899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
November 11, 2016
Completion date
March 31, 2023
Enrollment
45 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma